Recently, adagrasib and sotorasib showed excellent efficacy for NSCLC with KRAS G12C mutation [36, 37], and combination of ICIs and KRAS mutation might provide better survival than monotherapy. Here, KRAS is linked to non-small cell lung carcinoma.